Abstract
While opioids are very effective analgesics for treating acute pain, humans have struggled with opiate addiction for millenia. An opium abuse epidemic in the early 1900’s led the US government to develop a systematic research infrastructure and scientific plan to produce new compounds with analgesic properties but without abuse liability. This review describes the techniques that were developed for testing in the human laboratory, including empirically derived outcome measures and required elements for human abuse potential assessment. The evaluation and characterization of semi-synthetic and synthetic opioids, including full mu opioid agonists, partial agonists and mixed agonist-antagonists, are described across several decades of research. Finally, the prescription opioid epidemic beginning in the 1990’s in the US led to a resurgence in abuse potential evaluations, and the application of these methods to the study of novel abuse-deterrent formulations is discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abreu ME, Bigelow GE, Fleisher L, Walsh SL (2001) Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 154:76–84
Alves EA, Soares JX, Afonso CM, Grund JP, Agonia AS, Cravo SM, Netto AD, Carvalho F, Dinis-Oliveira RJ (2015) The harmful chemistry behind “krokodil”: street-like synthesis and product analysis. Forensic Sci Int 257:76–82
Ardakani YH, Rouini MR (2007) Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers. Biopharm Drug Dispos 28:527–534
Babalonis S, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL (2013) Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend 129:116–124
Babalonis S, Lofwall MR, Nuzzo PA, Walsh SL (2014) Pharmacodynamic effects or oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans. Addict Biol e-pub ahead of print
Balster RL, Bigelow GE (2003) Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13–S40
Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM (2000) Comparative abuse liability of intravenously administered remifentanil and fentanyl. J Clin Psychopharmacol 20:597–606
Bickel WK, Preston KL, Bigelow GE, Liebson IA (1986) Three-way drug discrimination in post-addict volunteers: hydromorphone, pentazocine, and saline. NIDA Res Monogr 67:177–183
Blanch B, Pearson SA, Haber PS (2014) An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 78:1159–1166
Campbell ND, Olsen JP, Walden L (2008) The narcotic farm the rise and fall of America’s first prison for drug addicts. Abrams Books, New York
Carter LP, Griffiths RR (2009) Principles of laboratory assessment of drug abuse liability and implictations for clinical development. Drug Alcohol Depend (in press)
Casati A, Sedefov R, Pfeiffer-Gerschel T (2012) Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 18:228–245
CDC (2016) CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Morb Mortal Wkly Rep 65:1–49
Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Reyo RA (2015) The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 162:276–286
Clark NC, Lintzeris N, Muhleisen PJ (2002) Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med J Aust 176:166–167
Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC (2014) Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig 34:421–429
Comer SD, Collins ED, MacArthur RB, Fischman MW (1999) Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology 143:327–338
Comer SD, Collins ED, Fischman MW (2002) Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 301:266–276
Comer SD, Sullivan MA, Walker EA (2005) Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 315:1320–1330
Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL (2008a) The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96:1–15
Comer SD, Sullivan MA, Whittington RA, Vosberg SK, Kowalczyk WJ (2008b) Abuse liabliity of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33:1179–1191
Comer SD, Sullivan MA, Vosburg SK, Kowalczyk WJ, Houser J (2010) Abuse liability of oxycodone as a function of pain and drug use history. Drug Alcohol Depend 109:130–138
Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O’Brien C, O’Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL (2012) Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain 153:2315–2324
Comer SD, Metz VE, Cooper ZD, Kowalczyk WJ, Jones JD, Sullivan MA, Manubay JM, Vosburg SK, Smith ME, Peyser D, Saccone PA (2013) Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. Behav Pharmacol 24:504–516
Commiskey S, Fan L-W, Ho IK, Rockhold RW (2005) Butorphanol: effects of a prototypical agonist-antagonist analgesic on k-opioid receptors. J Pharmacol Sci 98:109–116
Compton WM, Volkow ND (2006) Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 83(Suppl 1):S4–S7
Cowan A, Lewis JW, Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537–545
CSAT (2004) Clinical guidelines for buprenorphine in the treatment of opioid addiction. Substance abuse and mental health services administration
de Quincy T (1823) Confessions of an English Opium-eater. Taylor and Hessey, London
Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL (2005) Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496–1509
Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC (2010) Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology 211:303–312
Duke AN, Bigelow GE, Lanier RK, Strain EC (2011) Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther 338:255–262
Eddy NB (1956) Synthetic substances with morphine-like effect. Bull World Health Organ 114:353–402
Eddy NB (1973) The national research council involvement in the opiate problem. National Academy of Sciences, Washington, DC
Eddy NB, Lee LE Jr (1959) The analgesic equivalence to morphine and relative side action liability of oxymorphone (14-hydroxydihydro morphinone). J Pharmacol Exp Ther 125:116–121
Eddy NB, Lee LE Jr, Harris C (1959) Physical dependence and tolerance in relation to various analgesics in patients suffering from chronic pains; comparison between morphine, oxymorphone and anileridine. Bull World Health Organ 20:1245–1256
Eddy NB, Friebel H, Hahn KJ, Halbach H (1968) Codeine and its alternates for pain and cough relief. I. Codeine, exclusive of its antitussive action. Bull World Health Organ 38:673–741
Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH (2006) The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102:146–150
Epstein DH, Preston KL, Jasinski DR (2006) Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychiatry 73:90–99
FDA (2009) Format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications. In: U.S. Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (Ed.). U.S. Department of Health and Human Services, Rockville, MD
FDA (2010) Guidance for industry: assessment of abuse potential of drugs. In: U.S. Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER) (Ed.), Silver Spring, MD
FDA (2015) Abuse-deterrent opioids—evaluation and labeling guidance for industry. In: U.S. Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER) (ed) U.S. Department of Health and Human Services
Fischer B, Rehm J, Kirst M, Casas M, Hall W, Krausz M, Metrebian N, Reggers J, Uchtenhagen A, van den Brink W, van Ree JM (2002) Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health 12:228–234
Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, Strang J, van den Brink W (2007) Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health 84:552–562
Fischer B, Jones W, Murphy Y, Ialomiteanu A, Rehm J (2015) Recent developments in prescription opioid-related dispensing and harm indicators in Ontario, Canada. Pain Physician 18:E659–E662
Fraser HF, Rosenberg DE (1964) Studies on the human addiction liability of 2′-hydroxy-5, 9-dimethyl-2-(3,3-dimethylallyl)-6, 7-benzmorphan (WIN 20, 228): a weak narcotic antagonist. J Pharmacol Exp Ther 143:149–156
Fraser HF, Van Horn GG, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude of opiate addicts toward opiate-like drugs, (B) A short-term direct” addiction test. J Pharmacol Exp Ther 133:371–378
Fraser HF, Nash TL, Vanhorn GD, Isbell H (1976) Use of miotic effect in evaluating analgesic drugs in man. 1954 (proceedings). NIDA Res Monogr, p 60
Fraser HF, Kay DC, Yeh SY, Gorodetzky CW, Dewey WL (1978) Possible effects of normetabolites on the subjective and reinforcing characteristics of opioids in animals and man. Drug Alcohol Depend 3:301–318
Greenwald MK (2008) Behavioral economic analysis of drug preference using multiple choice procedure data. Drug Alcohol Depend 93:103–110
Greenwald MK, Stitzer ML (1998) Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine. Drug Alcohol Depend 53:17–30
Greenwald MK, June HL, Stitzer ML, Marco AP (1996) Comparative clinical pharmacology of short-acting mu opioids in drug abusers. J Pharmacol Exp Ther 277:1228–1236
Haertzen CA (1974) An overview of addiction research center inventory scales (ARCI): an appendix and manual of scales. In: Abuse, N.I.O.D. (ed) Department of Health, Education and Welfare, Rockville, MD
Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM (2014) Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol 54:468–477
Heishman SJ, Schuh KJ, Schuster CR, Henningfield JE, Goldberg SR (2000) Reinforcing and subjective effects of morphine in human opioid abusers: effect of dose and alternative reinforcer. Psychopharmacology 148:272–280
Hill JL, Zacny JP (2000) Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology 152:31–39
Horan PJ, Ho IK (1989) Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol Biochem Behav 34:847–854
Isbell H, Vogel VH (1949) The addiction liability of methadon (amidone, dolophine, 10820) and its use in the treatment of the morphine abstinence syndrome. Am J Psychiatry 105:909–914
Isbell H, Wikler A et al (1947) Tolerance and addiction liability of 6-dimethylamino-4-4-diphenylheptanone-3 (methadon). J Am Med Assoc 135:888–894
Jaffe JH, Martin WR (1991) Opioid analgesics and antagonists. In: Gilman AG, Rall RW, Nies AS, Taylor P (eds) Goodman and gilman’s the pharmacological basis of therapeutics. Maxwell Macmillan International Editions, Elmsford, New York, pp 485–521
Jasinski DR (1977) Assessment of the abuse potentiality of morphinelike drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, Berlin, pp 197–258
Jasinski DR, Mansky PA (1972) Evaluation of nalbuphine for abuse potential. Clin Pharmacol Ther 13:78–90
Jasinski DR, Nutt JG (1972) Progress report on the assessment program of the NIMH addiction research center. In: U.S. Department of Health, E., and Welfare, Public Health Service, Health Services and Mental Health Administration, National Institute of Mental Health, (ed) National, Lexington, Kentucky, pp 442–477
Jasinski DR, Preston KL (1986) Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend 17:301–310
Jasinski DR, Martin WR, Hoeldtke RD (1970) Effects of short- and long-term administration of pentazocine in man. Clin Pharmacol Ther 11:385–403
Jasinski DR, Griffith JD, Pevnick JS, Clark SC (1975) Progress report on studies for he clinical pharmacology section of the addiction research center. National Academy of Sciences, Washington, DC, pp 121–161
Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501–516
Jasinski DR, Fudala PJ, Johnson RE (1989) Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 45:513–519
Jasinski DR, Preston KL, Sullivan JT, Testa MP (1993) Abuse potential of oral tramadol. In: 55th Annual meeting of the college on problems of drug dependence, p 103
Jones JD, Madera G, Comer SD (2014) The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. Pharmacol Biochem Behav 122:299–306
Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD (2015) Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addict Biol 20:784–798
Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM (1997) Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 281:103–108
Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li NY, Sawe J, Tyndale RF, Sellers EM (2000) Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J Clin Psychopharmacol 20:435–444
Kim I, Barnes AJ, Oyler JM, Schepers R, Joseph RE Jr, Cone EJ, Lafko D, Moolchan ET, Huestis MA (2002) Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Clin Chem 48:1486–1496
Klous MG, Van den Brink W, Van Ree JM, Beijnen JH (2005) Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend 80:283–295
Lamas X, Farre M, Cami J (1994) Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers. J Pharmacol Exp Ther 268:1485–1492
Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, Henningfield JE, Goldberg SR (1991) The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 259:1165–1173
Lewis JW (1974) C-bridged derivatives of thebaine and oripavine. Adv Biochem Pharmacol 8:123–136
Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J (2007) Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend 91:187–194
Lofwall MR, Walsh SL (2014) A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med 8:315–326
Lofwall MR, Nuzzo PA, Walsh SL (2012) Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers. Drug Alcohol Depend 123:229–238
Marsch LA, Bickel WK, Badger GJ, Rathmell JP, Swedberg MD, Jonzon B, Norsten-Hoog C (2001) Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 299:1056–1065
Martin WR (1983) Pharmacology of opioids. Pharmacol Rev 35:283–323
McAvoy BR, Dobbin MD, Tobin CL (2011) Over-the-counter codeine analgesic misuse and harm: characteristics of cases in Australia and New Zealand. NZ Med J 124:29–33
McNair DM, Lorr M, Droppleman LF (1971) EITS manual for the profile of mood states. Educational and Industrial Testing Service, San Diego
Mendelson J, Jones RT, Welm S, Baggot M, Fernandez I, Melby AK, Nath RP (1999) Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology 141:37–46
Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL (2011) The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 106:1460–1473
Middleton LS, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL (2012) Intranasal oxycodone self-administration in non-dependent opioid abusers. Exp Clin Psychopharmacol 20:310–317
Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM (1993) CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54:463–472
Peters RJ Jr, Williams M, Ross MW, Atkinson J, Yacoubian GS Jr (2007) Codeine cough syrup use among African-American crack cocaine users. J Psychoactive Drugs 39:97–102
Pickworth WB, Johnson RE, Holicky BA, Cone EJ (1993) Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 53:570–576
Pircio AW, Gylys JA, Cavanagh RL, Buyniski JP, Bierwagen ME (1976) The pharmacology of butorphanol, a 3, 14-dihydroxymorphinan narcotic antagonist analgesic. Arch Int Pharmacodyn Ther 220:231–257
Preston KL, Bigelow GE (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264:813–823
Preston KL, Bigelow GE (1994) Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther 271:48–60
Preston KL, Walsh SL (1998) Evaluating abuse liability: methods and predictive value. In: Karch SB (ed) drug abuse handbook. CRC Press, Boca Raton, pp 276–306
Preston KL, Bigelow GE, Liebson IA (1987) Comparative evaluation of morphine, pentacozine and ciramadol in postaddicts. J Pharmacol Exp Ther 240:900–910
Preston KL, Bigelow GE, Liebson IA (1988) Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther 246:441–448
Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989a) Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther 250:184–196
Preston KL, Bigelow GE, Liebson IA (1989b) Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther 248:929–937
Preston KL, Bigelow GE, Liebson IA (1990) Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacol Biochem Behav 37:511–522
Preston KL, Jasinski DR, Testa M (1991) Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 27:7–17
Preston KL, Liebson IA, Bigelow GE (1992) Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. J Pharmacol Exp Ther 261
PurduePharma (2015) OXYCONTIN—oxycodone hydrochloride tablet, film coated, extended release Package Insert. In: LP, P.P. (ed)
Romach MK, Schoedel KA, Sellers EM (2014) Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology 87:81–90
Rosado J, Walsh SL, Bigelow GE, Strain EC (2007) Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend 90:261–269
Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM (2011) Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. J Opioid Manag 7:179–192
Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E (2012) Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta) tablets in nondependent recreational opioid users. J Opioid Manag 8:315–327
Schuh KJ, Walsh SL, Bigelow GE, Preston KL, Stitzer ML (1996) Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther 278:836–846
Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR (2014) Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155:1829–1835
Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL (2010) Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology 212:193–203
Stoops WW, Lofwall MR, Nuzzo PA, Craig LB, Siegel AJ, Walsh SL (2012) Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology 223:427–438
Stoops WW, Glaser PE, Rush CR (2013) Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users. Psychopharmacology 228:255–262
Strain EC, Preston KL, Liebson IA, Bigelow GE (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 261:985–993
Strain EC, Preston KL, Liebson IA, Bigelow GE (1993) Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther 267:624–634
Strain EC, Preston KL, Liebson IA, Bigelow GE (1995) Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 272:628–638
Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE (1997) The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology 129:329–338
Strain EC, Stoller K, Walsh SL, Bigelow GE (2000) Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 148:374–383
Sullivan MA, Vosburg SK, Comer SD (2006) Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189:37–46
Toll L, Bruchas MR, Calo G, Cox BM, Zaveri NT (2016) Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 68:419–457
Tompkins DA, Smith MT, Bigelow GE, Moaddel R, Venkata SL, Strain EC (2014) The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males. Clin J Pain 30:36–45
Umbricht A, Huestis MA, Cone EJ, Preston KL (2004) Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 24:479–487
Van Zee A (2009) The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health 99:221–227
Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, Kropp TJ, Verbois SL (2011) Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 59:385–390
Walker DJ, Zacny JP (1998) Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology 140:191–201
Walker DJ, Zacny JP (1999) Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther 289:1454–1464
Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569–580
Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML (1995a) Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 119:268–276
Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995b) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274:361–372
Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151–162
Walsh SL, Chausmer AE, Strain EC, Bigelow GE (2008a) Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology 196:143–155
Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr (2008b) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98:191–202
Walsh SL, Heilig M, Nuzzo PA, Henderson P, Lofwall MR (2012) Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol e-pub ahead of print
Webster LR, Bath B, Medve RA, Marmon T, Stoddard GJ (2012) Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med 13:790–801
Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE (1992) Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 30:263–274
White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL (2015) The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther 352:98–109
Wikler A, Fraser HF, Isbell H (1953) N-Allylnormorphine: effects of single doses and precipitation of acute abstinence syndromes during addiction to morphine; methadone or heroin in man (post addicts). J Pharmacol Exp Ther 109:8–20
Zacny JP, Lichtor SA (2008) Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology 196:105–116
Zacny JP, Gutierrez S (2009) Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend 101:107–114
Zacny JP, Lichtor JL, Zaragoza JG, de Wit H (1992) Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology 107:319–326
Zacny JP, Lichtor JL, Binstock W, Coalson DW, Cutter T, Flemming DC, Glosten B (1993) Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers. Psychopharmacology 111:306–314
Zacny JP, Lichtor JL, Thapar P, Coalson DW, Flemming D, Thompson WK (1994) Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther 270:579–588
Zacny JP, McKay MA, Toledano AY, Marks S, Young CJ, Klock PA, Apfelbaum JL (1996) The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. Drug Alcohol Depend 42:133–142
Zacny JP, Gutierrez S, Bolbolan SA (2005) Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users. Drug Alcohol Depend 78:243–252
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Walsh, S.L., Babalonis, S. (2016). The Abuse Potential of Prescription Opioids in Humans—Closing in on the First Century of Research. In: Nielsen, S., Bruno, R., Schenk, S. (eds) Non-medical and illicit use of psychoactive drugs. Current Topics in Behavioral Neurosciences, vol 34. Springer, Cham. https://doi.org/10.1007/7854_2016_448
Download citation
DOI: https://doi.org/10.1007/7854_2016_448
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-60014-7
Online ISBN: 978-3-319-60016-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)